CRISPR Therapeutics AG (CRSP)
|Net Income (ttm)||-392.30M|
|Trading Day||May 14|
|Day's Range||101.82 - 108.42|
|52-Week Range||58.02 - 220.20|
Nkarta Inc (NASDAQ: NKTX) has collaborated with CRISPR Therapeutics AG(NASDAQ: CRSP) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The companies will split all th...
One company is setting itself apart in a crowded field.
ZUG, Switzerland and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...
CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncolog...
ZUG, Switzerland and CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...
CRISPR Therapeutics' (CRSP) earnings and revenues miss estimates in the first quarter of 2021. Focus on pipeline development.
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -4.14% and -89.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- Granted Priority Medicines designation by the European Medicines Agency for CTX001™ for transfusion-dependent beta thalassemia (TDT)-
The Nasdaq gained ground to start the week.
Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCR...
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agen...
BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the Europe...
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $126.55, marking a +0.52% move from the previous day.
On CRISPR Therapeutics' (CRSP) first-quarter earnings call, investor focus will be on updates of the company's progress with the development of its lead gene-editing candidate, CTX001.
Both of these stocks have struggled in recent weeks, which means it might be a good time to initiate a position.
Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercializati...
- Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001-
A "sell" rating is one thing, but a price target barely half of the Thursday close? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it.
And they all have one key thing in common.
CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing...
ZUG, Switzerland and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...
Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.
Old crystal balls for viewing fiscal discipline never foresaw this golden age of tech innovation and ultra-low inflation.
The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.
Last month, we talked about why investors may want to wait for better levels to enter into the CRSP stock. Since then, the stock has seen a correction of over 28%.
CRISPR Therapeutics AG (CRSP) closed at $114.60 in the latest trading session, marking a -0.82% move from the prior day.
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $131.10, marking a +0.41% move from the previous day.
It's a firm maybe.
Gene editing has the potential to revolutionize medicine. With CRISPR Therapeutics leading the way, CRSP stock should benefit.
Tesla's great, but these Cathie Wood favorites have even better growth prospects.
With possibly the worst of the novel coronavirus pandemic over, on the surface CRSP stock seems to be a worthwhile rebound pick. However, the technical outlook suggests otherwise.
CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting
ZUG, Switzerland and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...
Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players. The post Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT...
Crispr Therapeutics offers one of the next big technologies and today shares of CRSP stock afford investors access to growth at a discount. The post Why CRSP Stock Is a Less Dicey Risk Asset Today appea...
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $114.65, marking a -0.73% move from the previous day.
One analyst thinks the company's foundational gene-editing tools have far more potential than many realize.
The companies with game-changing technology are often the best growth picks.
A few months back we talked about why the rally in CRSP stock may continue given the positive developments around CTX001, an experimental gene therapy for people with sickle cell disease and transfusion...
CRISPR Therapeutics (CRSP) misses estimates for both earnings and revenues in the fourth quarter of 2020. Focus on pipeline development.
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
- More than 20 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021 -
Bear of the Day: CRISPR Therapeutics (CRSP)
CRISPR Therapeutics AG (CRSP) closed at $168.81 in the latest trading session, marking a +0.61% move from the prior day.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate... [Read more...]
|IPO Date |
Oct 19, 2016
|Stock Exchange |
|Ticker Symbol |
According to 18 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is 160.18, which is an increase of 50.21% from the latest price.